2013 Annual Meeting | NINDS Colloquium

Date Tuesday 03/19/13

Time 12:00 PM - 02:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Colloquium

Director(s) Walter J. Koroshetz, MD, FAAN

Topic(s)

Learning Objectives Participants will have some understanding of how poor access of patients to clinical trials is damaging the US research effort. All participants will benefit from the sharing of ideas and best practices as to how this crisis might be alleviated.

Participants will learn about new initiatives funded by NINDS to improve treatment of patients with neurological disorders.

Clinical researchers will also gain useful knowledge of how to use the common data elements in their research.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Interactive, Audience Participation

Event Timeline
12:00 PM - 12:05 PM		Research in Neurology: Changing the Culture Walter J. Koroshetz, MD, FAAN
12:05 PM - 12:15 PM		Recruitment for Clinical Trials: A Patient Advocate Perspective Ronald Bartek
12:25 PM - 12:35 PM		Innovation and Creativity in Recruiting Patients to Alzheimers Research Jeffree Itrich, MSW, MJ
12:35 PM - 12:45 PM		Lessons Learned From Clinical Trials in Cancer Patrick Y. Wen, MD, FAAN
12:45 PM - 12:55 PM		Research in Practice James C. Stevens, MD, FAAN
01:05 PM - 01:15 PM		The Barriers to Research: Potential Solutions Bruce Sigsbee, MD, FAAN
01:15 PM - 02:00 PM		Tools for Clinical Research: Data Standards and NeuroNEXT Petra Kaufmann, MD, FAAN

Faculty Disclosures
Walter J. Koroshetz, MD, FAAN	Dr. Koroshetz has nothing to disclose.
Bruce Sigsbee, MD, FAAN	No disclosure on file
James C. Stevens, MD, FAAN	Dr. Stevens has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Physicians Health Plan.
Patrick Y. Wen, MD, FAAN	Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Black Diamond . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celularity. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chimerix. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Day One Bio . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genenta. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Glaxo Smith Kline . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mundipharma. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvation Bio . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prelude Therapeutics . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sagimet. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sapience. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vascular Biogenics . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for VBI Vaccines . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneca . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Black Diamond . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celularity. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chimerix. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Day One Bio . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genenta. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Glaxo Smith Kline . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mundipharma. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nuvation Bio. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novocure. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prelude Therapeutics. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sagimet. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sapience. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vascular Biogenics . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VBI Vaccines . Dr. Wen has received research support from Astra Zeneca . Dr. Wen has received research support from Black Diamond . Dr. Wen has received research support from Bristol Meyers Squibb . Dr. Wen has received research support from Celgene. Dr. Wen has received research support from Chimerix. Dr. Wen has received research support from Eli Lily . Dr. Wen has received research support from Erasca. Dr. Wen has received research support from Genentech/Roche . Dr. Wen has received research support from Kazia . Dr. Wen has received research support from MediciNova. Dr. Wen has received research support from Merck. Dr. Wen has received research support from Novartis. Dr. Wen has received research support from Nuvation Bio . Dr. Wen has received research support from Servier. Dr. Wen has received research support from Vascular Biogenics . Dr. Wen has received research support from VBI Vaccines . Dr. Wen has received publishing royalties from a publication relating to health care.
David R. Lynch, MD, PhD	The institution of Dr. Lynch has received research support from reata. The institution of Dr. Lynch has received research support from PTC. Dr. Lynch has received intellectual property interests from a discovery or technology relating to health care.
Petra Kaufmann, MD, FAAN	Dr. Kaufmann has received personal compensation for serving as an employee of Affinia Therapeutics. Dr. Kaufmann has received personal compensation for serving as an employee of Vigil Neuroscience. Dr. Kaufmann has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for DTx. Dr. Kaufmann has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Taysha Gene Therapies. Dr. Kaufmann has stock in Vigil Neuroscience. The institution of an immediate family member of Dr. Kaufmann has received research support from Cystic Fibrosis Foundation . Dr. Kaufmann has a non-compensated relationship as a Member of a Scientific Advisory Board with NIH that is relevant to AAN interests or activities.
Ronald Bartek	No disclosure on file
Jeffree Itrich, MSW, MJ	No disclosure on file

��ɫ��

��ɫ��